Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Varespladib - Ophirex

Drug Profile

Varespladib - Ophirex

Alternative Names: A-001; A-002; LY-315920; LY-333013; Methyl-varespladib; S-3013; S-5920; Varespladib methyl

Latest Information Update: 12 Jul 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Eli Lilly and Company; Shionogi
  • Developer Anthera Pharmaceuticals; Ophirex; University Health Network
  • Class Acetic acids; Anti-inflammatories; Antirheumatics; Indoles; Small molecules
  • Mechanism of Action Phospholipase A2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Acute lung injury
  • New Molecular Entity Yes

Highest Development Phases

  • Preclinical Snake venom poisoning
  • Discontinued Acute coronary syndromes; Acute lung injury; Coronary artery disease; Multiple organ failure; Systemic inflammatory response syndrome

Most Recent Events

  • 03 Mar 2020 Ophirex plans clinical trials for Snake venom poisoning
  • 24 Jun 2018 Biomarkers information updated
  • 23 Mar 2012 Discontinued - Phase-III for Acute coronary syndromes in Australia (PO)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top